Inventor · disambiguated record
Wafik S. El-Deiry
Also filed as: EL-DEIRY WAFIK · EL-DEIRY WAFIK S
25 granted patents·25 pending applications·86 citations·filing 1995–2025
94Inventor score
Files withUNIV BROWN16INSTITUTE FOR CANCER RES13PENN STATE RES FOUND10UNIV PENNSYLVANIA3EL-DEIRY WAFIK S2
Top patents by PatentIndex Score
50 records- 0190USRE46290ESmall molecule trail gene induction by normal and tumor cells as an anticancer therapyPENN STATE RES FOUND·Filed 2015·Granted Jan 31, 2017·6 cites·12 claims
- 0290US2024415841A1Small molecule trail gene induction by normal and tumor cells as an anticancer therapyPENN STATE RES FOUND·Filed 2024·Application pending·0 cites
- 0389US8673923B2Small molecule trail gene induction by normal and tumor cells as an anticancer therapyEL-DEIRY WAFIK S·Filed 2012·Granted Mar 18, 2014·15 cites·12 claims
- 0488US10987356B2Dual inhibition of CDK and HSP90 destabilize H1F1 α and synergistically induces cancer cell deathINSTITUTE FOR CANCER RES·Filed 2019·Granted Apr 27, 2021·2 cites·19 claims
- 0583US11578324B2miR-3132 upregulation of the TRAIL pathway and apoptotic activity in cancer cellsINSTITUTE FOR CANCER RES·Filed 2019·Granted Feb 14, 2023·2 cites·13 claims
- 0682US12036223B2Small molecule trail gene induction by normal and tumor cells as an anticancer therapyPENN STATE RES FOUND·Filed 2022·Granted Jul 16, 2024·0 cites·9 claims
- 0781US12344599B2Prodigiosin analogs and methods of useINSTITUTE FOR CANCER RES·Filed 2024·Granted Jul 1, 2025·0 cites·16 claims
- 0879US5807692AP21WAF1 derivatives and diagnostic methodsUNIV JOHNS HOPKINS·Filed 1995·Granted Sep 15, 1998·32 cites·17 claims
- 0978US11993589B2Prodigiosin analogs and methods of useINSTITUTE FOR CANCER RES·Filed 2022·Granted May 28, 2024·0 cites·8 claims
- 1078US9629842B2Small molecule TRAIL gene induction by normal and tumor cells as an anticancer therapyPENN STATE RES FOUND·Filed 2016·Granted Apr 25, 2017·1 cites·22 claims
- 1176US7553955B2Molecular beacons, methods and kits for detecting DNA damage responseUNIV PENNSYLVANIA·Filed 2006·Granted Jun 30, 2009·3 cites·23 claims
- 1275US10322123B2Compound for anti-cancer therapy that acts by targeting GOF mutant P53 and stimulates P73 to restore the P53 pathway signalingPENN STATE RES FOUND·Filed 2015·Granted Jun 18, 2019·2 cites·17 claims
- 1375US9452165B2Small molecule TRAIL gene induction by normal and tumor cells as an anticancer therapyPENN STATE RES FOUND·Filed 2015·Granted Sep 27, 2016·1 cites·22 claims
- 1475US9072744B1Small molecule trail gene induction by normal and tumor cells as an anticancer therapyPENN STATE RES FOUND·Filed 2014·Granted Jul 7, 2015·1 cites·27 claims
- 1575US9061032B2Small molecule trail gene induction by normal and tumor cells as an anticancer therapyPENN STATE RES FOUND·Filed 2014·Granted Jun 23, 2015·1 cites·11 claims
- 1675US5871968AP21WAF1 derivatives and diagnostic methodsUNIV JOHNS HOPKINS·Filed 1997·Granted Feb 16, 1999·18 cites·4 claims
- 1774US10729692B2Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell deathINSTITUTE FOR CANCER RES·Filed 2018·Granted Aug 4, 2020·1 cites·5 claims
- 1873US12071622B2miR-3132 upregulation of the trail pathway and apoptotic activity in cancer cellsINSTITUTE FOR CANCER RES·Filed 2023·Granted Aug 27, 2024·0 cites·11 claims
- 1972US11203598B2Compounds for repressing cancer cell growthINSTITUTE FOR CANCER RES·Filed 2019·Granted Dec 21, 2021·1 cites·4 claims
- 2071US11859183B2Treatment of tumors with miRNA targeting CDK4/CDK6INSTITUTE FOR CANCER RES·Filed 2021·Granted Jan 2, 2024·0 cites·8 claims
- 2169US2025135196A1Compositions, systems, and methods for treating cancer using tumor treating fields with inhibitors of mif, mica, and/or micbUNIV BROWN·Filed 2024·Application pending·0 cites
- 2268US11535608B2Prodigiosin analogs and methods of useINSTITUTE FOR CANCER RES·Filed 2020·Granted Dec 27, 2022·0 cites·18 claims
- 2368US2024423994A1Targeting immune suppression after atr inhibitionUNIV BROWN·Filed 2024·Application pending·0 cites
- 2467US2024309090A1Modulation of androgen signaling to innate immune killing of prostate cancerUNIV BROWN·Filed 2024·Application pending·0 cites
- 2566US2025049918A1Targeting the immune suppressive tumor microenvironmentUNIV BROWN·Filed 2023·Application pending·0 cites
- 2665US10870640B2Prodigiosin analogs and methods of useINSTITUTE FOR CANCER RES·Filed 2019·Granted Dec 22, 2020·0 cites·19 claims
- 2765US2023414715A1Trail compounds for reducing cancer treament side effectsUNIV BROWN·Filed 2023·Application pending·0 cites
- 2864US2024050431A1Neuroendocrine differentiation in imipridone cancer treatmentUNIV BROWN·Filed 2023·Application pending·0 cites
- 2964US2025084486A1Frequent egfr and ntrk somatic mutations in colorectal cancer (crc) with microsatellite instability (msi)INSTITUTE FOR CANCER RES D/B/A THE RES INSTITUTE OF FOX CHASE CANCER CENTER·Filed 2024·Application pending·0 cites
- 3064US2024053326A1Testing colon cancer drugs for immunomodulatory effectsUNIV BROWN·Filed 2023·Application pending·0 cites
- 3164US2016151403A1Small molecule modulators of p53 family signalingUNIV PENNSYLVANIA·Filed 2014·Application pending·0 cites
- 3264US2017224690A1Small molecule trail gene induction by normal and tumor cells as an anticancer therapy and tumor cells as an anticancer therapyPENN STATE RES FOUND·Filed 2017·Application pending·0 cites
- 3364US2024041830A1Circulating biomarkers of response to pd-1/pd-l1 blockade and gsk-3 inhibitionUNIV BROWN·Filed 2023·Application pending·0 cites
- 3463US11034959B2Treatment of tumors with miRNA targeting CDK4/CDK6INSTITUTE FOR CANCER RES·Filed 2018·Granted Jun 15, 2021·0 cites·8 claims
- 3563US10744133B2Compound for anti-cancer therapy that acts by targeting GOF mutant p53 and stimulates p73 to restore the p53 pathway signalingPENN STATE RES FOUND·Filed 2019·Granted Aug 18, 2020·0 cites·23 claims
- 3663US2023340614A1Treating tumors resulting in or from cns metastasis using mdm2/4 and cdkn2a inhibitorsUNIV BROWN·Filed 2023·Application pending·0 cites
- 3762US2024301505A1Urinary tract cancer treatment guided by mutational landscapeUNIV BROWN·Filed 2022·Application pending·0 cites
- 3861US2024191303A1Methods for optimizing the treatment of colorectal cancerUNIV BROWN·Filed 2022·Application pending·0 cites
- 3961US2023183356A1HIF-1a MODULATORS AND USES THEREOFUNIV BROWN·Filed 2022·Application pending·0 cites
- 4058US2024009170A1Inhibition of glycogen synthase kinase-3 (gsk-3)UNIV BROWN·Filed 2021·Application pending·0 cites
- 4156US2022073519A1Compounds For Repressing Cancer Cell GrowthINSTITUTE FOR CANCER RES D/B/A THE RES INSTITUTE OF FOX CHASE CANCER CENTER·Filed 2021·Application pending·0 cites
- 4255US12098428B2Frequent EGFR and NTRK somatic mutations in colorectal cancer (CRC) with microsatellite instability (MSI)INSTITUTE FOR CANCER RES·Filed 2018·Granted Sep 24, 2024·0 cites·14 claims
- 4355US2023330089A1Covid prevention and treatment using an integrin inhibitorUNIV BROWN·Filed 2023·Application pending·0 cites
- 4452US2015328310A1Methods and compositions relating to treatment of cancerALLEN JOSHUA E·Filed 2013·Application pending·0 cites
- 4548US2002169123A1Regulating apoptosis in TRAIL-resistant cancer cells, while protecting normal, non-cancerous cellsUNIV PENNSYLVANIA·Filed 2002·Application pending·0 cites
- 4648US2025325548A1Tumor suppressor p73 transcriptionally regulates c-flip to impede its priming of extrinsic apoptosis while an example switcher compound cb-7587351 degrades c-flip proteinUNIV BROWN·Filed 2025·Application pending·0 cites
- 4747US2023219957A1Small molecule cb002-analoges restore the p53 pathway and target s-phase checkpointUNIV BROWN·Filed 2021·Application pending·0 cites
- 4843US2010217129A1Angiogenesis monitoring using in vivo hyperspectral radiometric imagingEL-DEIRY WAFIK S·Filed 2008·Application pending·0 cites
- 4938US10654801B2Prodigiosin analogsINSTITUTE FOR CANCER RES·Filed 2017·Granted May 19, 2020·0 cites·8 claims
- 5033US2002048566A1Modulation of cellular apoptosis and methods for treating cancerFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Wafik S. El-Deiry files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →